William Blair Believes Silence Therapeutics (NASDAQ: SLN) Still Has Room to Grow

In a report released yesterday, Myles Minter from William Blair reiterated a Buy rating on Silence Therapeutics (SLNResearch Report). The company’s shares closed last Friday at $26.30, close to its 52-week high of $28.06.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 11.5% and a 48.4% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences.

Silence Therapeutics has an analyst consensus of Moderate Buy.

See today’s analyst top recommended stocks >>

Silence Therapeutics’ market cap is currently $756.6M and has a P/E ratio of -16.20. The company has a Price to Book ratio of 629.86.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.